Loading...
01/11 03:22
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presented mixed signals. Financial performance showed growth in sales but a slight decline in gross margin and increased net loss. Guidance was reiterated, with potential upside from U.S. initiatives. Regulatory issues and competitive pressures pose risks, while no shareholder return plans were announced. The Q&A highlighted management's confidence in future growth but lacked specifics on key metrics. Overall, the absence of strong positive catalysts or severe negatives suggests a neutral sentiment.
Worldwide Sales $22.5 million, a 20% increase from $18.9 million in the same period last year.
U.S. Revenue $14.2 million, an increase of 11% from $12.9 million over the prior year period.
International Revenue $8.3 million, a 39% increase from $6 million during the same period last year.
Gross Margin 73%, compared to 75% in the prior year period.
Total Operating Expenses $30.9 million, an 8% increase from $28.6 million in the first quarter of 2024.
Net Loss $14.4 million, compared to a net loss of $13.7 million for the same period of the prior year.
Adjusted EBITDA Loss $8.5 million, compared to $8 million in the first quarter of 2024.
Cash, Cash Equivalents and Marketable Securities $88.7 million, a decrease of $12.8 million from December 31, 2024.
LungTraX Detect: We are rolling out tools like LungTraX Detect to help our customers identify patients with severe emphysema who are already under their care.
CME Modules: In early April, we launched two new CME modules through Medscape that build on previous programs to educate clinicians.
AeriSeal CONVERT II trial: We continue to increase enrollment in activated centers around the world in our AeriSeal CONVERT II trial.
International Revenue Growth: In Q1, we delivered strong international year-over-year revenue growth of 39%, driven by strength in China and select international markets.
New U.S. Accounts: In Q1, we added 10 new U.S. accounts, ending the quarter with 285 active accounts.
Market Opportunity: We expect to accelerate penetration into our estimated $12 billion market opportunity.
Patient Engagement: We saw a record number of unique patient engagements driven by direct-to-patient initiatives.
Operational Efficiencies: We are marketing a new program that offers hospitals a third-party technology-enabled solution to manage patients through the workflow process.
Acquired Test and Treat Strategy: We made steady progress executing our acquired test and treat strategy, setting the stage for sustained growth and long-term success.
Expansion of Field Presence: This year we’re expanding our field presence by hiring therapy awareness specialists dedicated to community physician education.
Regulatory Issues: The company received a civil investigative demand from the U.S. Department of Justice related to the False Claims Act and the Anti-Kickback Statute, but the DOJ declined to intervene in the case.
Competitive Pressures: The company faces challenges in U.S. growth, which has moderated over the past four quarters, indicating pressure points in the patient funnel and a need for better connection between patients and physicians.
Supply Chain Challenges: The company is actively monitoring global trade policies, including tariffs, and assessing their potential impact on international revenue.
Economic Factors: Fluctuations in global currency markets could affect reported revenue growth, and the company is aware of the economic environment impacting their operations.
Market Awareness: Less than a third of pulmonologists have referred patients for evaluation due to a lack of familiarity with patient eligibility criteria, which the company is addressing through education initiatives.
Worldwide Sales: Pulmonx delivered worldwide sales of $22.5 million in Q1 2025, representing 20% growth year-over-year.
Revenue Guidance: The company reaffirmed its revenue guidance for 2025, expecting total revenue between $96 million and $98 million.
Market Opportunity: Pulmonx aims to penetrate a $12 billion market opportunity, targeting growth at or above 20% long-term.
Patient Engagement Initiatives: The company is increasing clinician and patient awareness through various educational programs and tools like LungTraX Detect.
International Growth: International revenue grew by 39% year-over-year, driven by strong demand in China and other markets.
AeriSeal Launch: The anticipated commercial launch of AeriSeal outside the U.S. is expected in 2026, expanding the addressable market by 20%.
Revenue Guidance: Full year 2025 revenue is projected to be in the range of $96 million to $98 million.
Gross Margin Guidance: Expected gross margin for the full year is approximately 74%, with improvements anticipated in the second half.
Operating Expenses Guidance: Full year operating expenses are projected to be between $133 million and $135 million.
Cash Flow Breakeven: The company is confident in achieving cash flow breakeven with current resources.
Shareholder Return Plan: Pulmonx Corporation has not announced any share buyback program or dividend program during the Q1 2025 earnings call.
The earnings call reveals mixed financial results with modest revenue growth and increased expenses, particularly in R&D. The guidance revision downward and management's inability to provide clear answers during the Q&A suggest challenges in execution and strategic direction. While international growth and gross margin improvements are positives, the lack of clarity on U.S. growth and strategic pathways, along with cash burn, contribute to a negative sentiment. The market is likely to react negatively to these uncertainties, resulting in a potential stock price decline of -2% to -8%.
The earnings call presents a mixed picture: international revenue growth is strong, but U.S. growth is lagging, and gross margins have declined. The reaffirmed guidance and cash flow breakeven target are positive, but the Q&A reveals uncertainties in U.S. growth and StratX trends. The flat Q3 outlook and cautious guidance for the second half, along with increased expenses, suggest a balanced sentiment. Without a market cap, the stock's reaction is uncertain, but the overall sentiment appears neutral, with no strong catalysts for significant movement in either direction.
The earnings call presented mixed signals. Financial performance showed growth in sales but a slight decline in gross margin and increased net loss. Guidance was reiterated, with potential upside from U.S. initiatives. Regulatory issues and competitive pressures pose risks, while no shareholder return plans were announced. The Q&A highlighted management's confidence in future growth but lacked specifics on key metrics. Overall, the absence of strong positive catalysts or severe negatives suggests a neutral sentiment.
The earnings call reveals several concerns: competitive pressures, supply chain challenges, and market adoption risks. Financial performance shows increased revenue but also rising expenses and a consistent net loss. The Q&A highlights uncertainty in guidance, lack of clarity on key initiatives, and potential tariff impacts. Despite some positive developments, such as international revenue growth, the overall sentiment is negative due to ongoing operational challenges and financial health concerns.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
